Charles Schwab Investment Management Inc. Has $14.14 Million Stock Holdings in Innoviva, Inc. (NASDAQ:INVA)

Charles Schwab Investment Management Inc. reduced its holdings in Innoviva, Inc. (NASDAQ:INVA - Free Report) by 11.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 732,296 shares of the biotechnology company's stock after selling 98,766 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 1.17% of Innoviva worth $14,141,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its position in shares of Innoviva by 3.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 51,487 shares of the biotechnology company's stock worth $785,000 after acquiring an additional 1,881 shares during the last quarter. QRG Capital Management Inc. grew its position in shares of Innoviva by 19.7% during the 2nd quarter. QRG Capital Management Inc. now owns 76,010 shares of the biotechnology company's stock worth $1,247,000 after buying an additional 12,512 shares during the period. SG Americas Securities LLC raised its stake in shares of Innoviva by 797.4% during the second quarter. SG Americas Securities LLC now owns 81,500 shares of the biotechnology company's stock worth $1,337,000 after buying an additional 72,418 shares during the last quarter. Hennion & Walsh Asset Management Inc. acquired a new position in Innoviva in the second quarter valued at approximately $167,000. Finally, SummerHaven Investment Management LLC boosted its stake in Innoviva by 1.7% in the second quarter. SummerHaven Investment Management LLC now owns 59,853 shares of the biotechnology company's stock valued at $982,000 after acquiring an additional 980 shares during the last quarter. 99.12% of the stock is owned by institutional investors and hedge funds.

Innoviva Trading Up 1.1 %

NASDAQ:INVA traded up $0.21 during mid-day trading on Monday, hitting $19.26. The company had a trading volume of 190,000 shares, compared to its average volume of 589,185. The firm has a market cap of $1.21 billion, a P/E ratio of 27.61 and a beta of 0.53. Innoviva, Inc. has a fifty-two week low of $14.32 and a fifty-two week high of $21.28. The business's fifty day moving average is $19.54 and its two-hundred day moving average is $18.34. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.64 and a current ratio of 1.79.

Innoviva (NASDAQ:INVA - Get Free Report) last issued its earnings results on Wednesday, November 6th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.27 by ($0.25). Innoviva had a net margin of 18.31% and a return on equity of 20.84%. The firm had revenue of $89.51 million during the quarter. As a group, research analysts expect that Innoviva, Inc. will post 0.33 earnings per share for the current year.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.